Skip to main content
CASI Pharmaceuticals, Inc. logo

CASI Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · CASI ISIN · US14757U2087 LEI · 549300RYDG4U21PJZ263 US Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2026-06-02 Board/Management Inform…
Country US United States of America
Listing US CASI

About CASI Pharmaceuticals, Inc.

https://www.casipharmaceuticals.com/

CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for organ transplantation and autoimmune diseases. The company's lead program is centered on CID-103, an investigational anti-CD38 monoclonal antibody. This therapy is being developed to address antibody-mediated rejection (AMR) in organ transplant recipients, a significant unmet medical need with no currently approved treatments. The mechanism of CID-103 targets B memory cells, plasmablasts, and persistent plasma cells that can contribute to organ rejection. The company is also exploring the potential of this anti-CD38 approach for treating various autoimmune diseases, such as immune thrombocytopenia (ITP).

Recent filings

Filing Released Lang Actions
FORM 6-K
Board/Management Information Classification · 90% confidence The document is a Form 6-K (a regulatory filing for a foreign private issuer) whose substantive content is an announcement that a director has resigned from the board, effective May 31, 2026. This is a clear change in the company’s board of directors, fitting the definition of Board/Management Information.
2026-06-02 English
20-F
Annual Report FY 2025
2026-05-15 English
6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed with the U.S. SEC by a foreign private issuer, CASI Pharmaceuticals, reporting the closing of the fourth tranche of a convertible note financing. It includes details about the convertible notes issued, terms, and forward-looking statements. Form 6-K is a periodic report used by foreign private issuers to disclose material information between annual reports. The content focuses on a capital raising event (issuance of convertible notes) rather than a full financial report or earnings release. The document is not an annual or interim report, audit report, or earnings release. It is a regulatory filing reporting a financing update. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is about 5,037 characters, containing substantive information about the financing transaction, not merely an announcement of a report publication or certification. Confidence is high given the clear description of the convertible note issuance and financing terms.
2026-04-20 English
6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by CASI Pharmaceuticals, Inc., which is a report of a foreign private issuer pursuant to SEC rules. It announces the commencement of trading on the OTCQB market. The document is relatively short (3835 characters) and primarily serves as an announcement rather than a detailed financial report. It does not contain financial statements or substantive financial data. It also includes forward-looking statements and a signature section. Given these characteristics, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-15 English
3 - CASI Pharmaceuticals, Inc. (0001962738) (Issuer)
Director's Dealing
2026-03-27 English
3 - CASI Pharmaceuticals, Inc. (0001962738) (Issuer)
Director's Dealing
2026-03-25 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.